TCGA-CN-4739-01A-02R-1514-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.31826484
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.210
- G2M_CHECKPOINT+0.150
- KRAS_SIGNALING_DN+0.140
- SPERMATOGENESIS+0.110
- E2F_TARGETS+0.070
- CHOLESTEROL_HOMEOSTASIS+0.060
- ALLOGRAFT_REJECTION-0.020
- ANDROGEN_RESPONSE-0.020
- ESTROGEN_RESPONSE_EARLY-0.030
- MITOTIC_SPINDLE-0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- INTERFERON_GAMMA_RESPONSE-0.450
- HYPOXIA-0.440
- ANGIOGENESIS-0.390
- MYC_TARGETS_V1-0.370
- OXIDATIVE_PHOSPHORYLATION-0.370
- TGF_BETA_SIGNALING-0.360
- TNFA_SIGNALING_VIA_NFKB-0.350
- GLYCOLYSIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1455060 | GTEX | — | 0.882 |
| 2 | SRR1471374 | GTEX | — | 0.869 |
| 3 | SRR627299 | GTEX | — | 0.866 |
| 4 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.866 |
| 5 | BS_4GTESTSE | Ganglioglioma | — | 0.864 |
| 6 | TCGA-QK-AA3J-01A-11R-A39I-07 | — | — | 0.864 |
| 7 | SRR1485789 | GTEX | — | 0.862 |
| 8 | 5ea84fac-788c-458f-b820-b80224a4dbc2 | — | — | 0.854 |
| 9 | SRR627453 | GTEX | — | 0.852 |
| 10 | SRR12696758 | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |